Skip to main content

Table 3 Tumor regression grade, acute toxicity, late toxicity (a), and analysis of the correlation between MN and NPB yields and TRG, acute and late toxicity (b). Information on tumor regression grade and late toxicity is missing in 3 and 6 patients, respectively

From: Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

a
  Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
TRG 1 14 45 50 19
Acute toxicity
 Skin 50 50 22 10 0
 Bladder 63 55 9 4 1
 Rectum 18 65 31 16 2
 Small bowel 51 54 18 5 4
Late toxicity
 Skin 110 16 0 0 0
 Bladder 105 4 2 14 1
 Rectum 88 12 19 2 5
b
  MN/BNL NPB/BNL
  3Gy in vitro End RCT (50.4Gy) 3 Gy in vitro End RCT (50.4Gy)
  Kendall’s τ [CI] P Kendall’s τ [CI] P Kendall’s τ [CI] P Kendall’s τ [CI] P
TRG 0.09 [−0.04–0.19] 0.18 −0.02 [−0.13–0.10] 0.78 −0.06 [−0.16–0.07] 0.42 −0.12 [−0.21–0.02] 0.09
Acute toxicity
 Skin 0.10 [−0.01–0.18] 0.13 0.04 [−0.08–0.14] 0.56 0.00 [− 0.12–0.12] 1.00 − 0.09 [− 0.18–0.04] 0.21
 Bladder − 0.01 [− 0.11–0.10] 0.88 0.06 [− 0.06–0.16] 0.36 0.09 [− 0.04–0.18] 0.21 0.04 [− 0.08–0.13] 0.61
 Rectum 0.13 [0.00–0.21] 0.06 0.02 [− 0.11–0.14] 0.82 − 0.17 [− 0.25 - -0.02] 0.01 − 0.10 [− 0.20–0.03] 0.15
 Small bowel −0.07 [− 0.17–0.05] 0.28 0.02 [− 0.10–0.13] 0.77 0.04 [− 0.07–0.14] 0.56 0.09 [− 0.04–0.18] 0.21
Late toxicity 0.07 [− 0.06–0.17] 0.30 −0.03 [− 0.15–0.10] 0.67 −0.07 [− 0.16–0.06] 0.33 −0.04 [− 0.14–0.08] 0.61
 Skin 0.00 [− 0.08–0.08] 1.00 −0.12 [− 0.13–0.01] 0.11 0.02 [− 0.07–0.09] 0.75 0.03 [− 0.06–0.09] 0.72
 Bladder −0.03 [− 0.10–0.07] 0.73 0.01 [− 0.09–0.10] 0.89 −0.10 [− 0.014–0.03] 0.17 −0.03 [− 0–09 - 0.06] 0.68
 Rectum 0.06 [− 0.06–0.14] 0.40 −0.10 [− 0.17–0.03] 0.18 0.04 [− 0.07–0.12] 0.57 0.02 [− 0.09–0.11] 0.83
  1. TRG tumor regression grading, RCT radiochemotherapy; MN: micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges